New Insights into the Precise Function of CAR T Cells

​ Chimeric antigen receptor (CAR) T-cell therapy modifies the patient's own T cells, otherwise known as natural killer cells or cytotoxic T lymphocytes, to enable the T cells to recognize and eliminate a target molecule, CD19, on the cancerous cells. While this form of immunotherapy has great potential in treating B-cell malignancies, relapse does occur in some patients. Researchers have gained new insights into the outcome and dynamics of CAR T-cell interactions in different anatomical sites, r...
Continue reading

B-Cell Malignancies: Treatment Advances in CAR T-Cell Therapy With Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®

Outcomes have improved in recent years for patients with B-cell malignancies such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia (ALL), but many patients continue to develop relapsed or refractory disease. In this interview with i3 Health, Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®, Oncology Clinical Nurse Specialist at the Ronald Reagan UCLA Medical Center, discusses advances in chimeric antigen receptor (CAR) T-cell therapy, which has been shown to produce significant...
Continue reading

Killing Leukemia Cells by Disrupting Amino Acid Consumption

Researchers at Winship Cancer Institute of Emory University found that inhibiting amino acid metabolism hinders leukemia cell growth. The investigators report that ASCT2, a transporter enzyme that carries amino acids into cells, is a potential therapeutic target for cancer. "So far, little progress has been made in finding therapeutic targets in amino acid metabolic pathways that can be harnessed to kill cancer cells but spare normal cells," remarked Cheng-Kui Qu, MD, PhD, Professor in the Depar...
Continue reading

Follicular Lymphoma: Types of T Cells Affect Outcome

Researchers have identified subtypes of T cells occurring within the follicular lymphoma (FL) microenvironment that have differing impacts on patients' chances of survival. With a median five-year survival of 74% for patients with FL treated with chemoimmunotherapy, this form of treatment has substantially improved outcomes. For a subset of patients who experience early disease progression, however, survival rates remain very low. Part of the reason for the poor outcome among these patients is a...
Continue reading

Glyphosate-Based Herbicides Linked to Non-Hodgkin Lymphoma

Researchers report that glyphosate, the herbicide commonly found in Roundup® (Monsanto Technology, LLC), which is used as a pesticide on produce, significantly increases the risk of developing non-Hodgkin lymphoma (NHL) in humans. "Our analysis focused on providing the best possible answer to the question of whether or not glyphosate is carcinogenic," remarked the senior author of the paper, Lianne Sheppard, PhD, Professor of Environmental and Occupational Health Sciences and Biostatistics at th...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.